|
| Press Releases |
|
 |
|
| Thursday, November 8, 2018 |
|
|
Eisai Commences Full-Scale Operation of New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly. more info >> |
|
| Monday, October 29, 2018 |
|
|
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD |
| Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease (CTAD) meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension (LTE) of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. more info >> |
|
| Friday, October 26, 2018 |
|
|
エーザイ、アルツハイマー病に伴う不規則睡眠覚醒リズム障害を対象とする「レンボレキサント」の最新データを第11回アルツハイマー病臨床試験会議（CTAD）において発表 |
| エーザイ、アルツハイマー病に伴う不規則睡眠覚醒リズム障害を対象とする「レンボレキサント」の最新データを第11回アルツハイマー病臨床試験会議（CTAD）において発表 more info >> |
|
|
Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease |
| Eisai Co., Ltd. announced that Eisai presented new data from Study 202, a Phase II evaluation of lemborexant, an investigational sleep-wake regulation agent, for the treatment of Irregular Sleep-Wake Rhythm Disorder (ISWRD) in patients with mild to moderate Alzheimer's disease. more info >> |
|
|
Eisai and Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease |
| Eisai presented the latest data from the Phase II clinical study (Study 201) of BAN2401 at a symposium session titled "Clinical and Biomarker Updates from BAN2401 Study 201 in Early Alzheimer's Disease" held on October 25 at the 11th CTAD conference in Barcelona, Spain. more info >> |
|
| Thursday, October 25, 2018 |
|
|
エーザイ、第33回がん免疫学会年次総会において「レンビマ(R)」（レンバチニブ）と「キイトルーダ(R)」（ペムブロリズマブ）併用療法の最新データおよび新規STINGアゴニストの探索研究について発表 |
| エーザイ、第33回がん免疫学会年次総会において「レンビマ(R)」（レンバチニブ）と「キイトルーダ(R)」（ペムブロリズマブ）併用療法の最新データおよび新規STINGアゴニストの探索研究について発表 more info >> |
|
|
Eisai to Present Latest Data on Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination and Exploratory Research |
| Eisai Co., Ltd. announced today that the latest data regarding its in-house discovered kinase inhibitor lenvatinib mesylate, in combination with Merck & Co.'s anti-PD-1 therapy pembrolizumab, and exploratory research on the STING (stimulator of interferon genes) agonist E7766 as cancer immunotherapy will be presented during the 33rd Annual Meeting of the SITC. more info >> |
|
| Tuesday, October 23, 2018 |
|
|
Eisai: Application Seeking Manufacturing and Marketing Approval in Japan Submitted for Parkinson's Disease Treatment Safinamide |
| Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced that an application seeking manufacturing and marketing approval in Japan was submitted as of today by Meiji for the Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide"). more info >> |
|
|
エーザイとMeiji、パーキンソン病治療剤サフィナミドの日本における製造販売承認申請 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）およびMeiji Seikaファルマ株式会社（本社：東京都、代表取締役社長：小林大吉郎、以下 Meiji）は、パーキンソン病に係る適応で開発を進めてきたME2125（開発コード、一般名：サフィナミドメシル酸塩、以下 サフィナミド）について、日本における製造販売承認申請を本日、Meijiが行いましたのでお知らせします。 more info >> |
|
| Monday, October 22, 2018 |
|
|
Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan |
| Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Maxon、リアルタイム建築ビジュアライゼーションソリューションでAEC市場に正式参入
Mar 17, 2026 23:05: JST
|
|
|
Maxon, 실시간 Archviz 솔루션으로 AEC 시장 공식 진출
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出即時Archviz解決方案，正式進軍AEC市場
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon推出实时Archviz解决方案，正式进军AEC市场
Mar 17, 2026 22:05 HKT/SGT
|
|
|
Maxon Marks Its Official Entry Into the AEC Market With Its Real-Time Archviz Solution
Mar 17, 2026 22:05 HKT/SGT
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00: JST
|
|
|
FinHarbor Introduces Rapid-Deployment Neobank Platform for 30-Day Go-Live
Mar 17, 2026 22:00 HKT/SGT
|
|
|
Geo Energy's Integrated Infrastructure Project Achieves 80% Completion; Secures Two Binding Term Sheets with Third Parties for 9 Million Tonnes Annual Haulage; Coal Prices Surge Amid Global Tensions
Mar 17, 2026 22:00 HKT/SGT
|
|
|
FILMART and EntertainmentPulse open today
Mar 17, 2026 21:41: JST
|
|
|
FILMART and EntertainmentPulse open today
Mar 17, 2026 20:41 HKT/SGT
|
|
|
鍋圈(2517.HK)核心經營利潤勁增 四店齊發驅動長期成長
Mar 17, 2026 20:30 HKT/SGT
|
|
|
锅圈(2517.HK)核心经营利润劲增 四店齐发驱动长期成长
Mar 17, 2026 20:24 HKT/SGT
|
|
|
GUOQUAN FOOD (2517.HK) Surging core operating profit, Four Stores Jointly Advancing with Concerted Efforts for Long-Term Growth
Mar 17, 2026 20:15 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP Provides Medals, Commemorative Items, and Trophies as Category Sponsor (Awards Ceremonies) for the LIGA.i Blind Soccer Top League 2025
Mar 17, 2026 21:00 JST
|
|
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 17, 2026 19:49 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
